Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Methylprednisolone for COVID-19 Pneumonia
NCT05002517Phase 3Unknown
- Sponsor
- Biogipuzkoa Health Research Institute
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in COVID-19 pneumonia (2 arms), sponsored by Biogipuzkoa Health Research Institute. Primary endpoints: PaO2/FiO2 ratio at 7 days, LDH, D-dimer, and ferritin levels at 7 days and 2 more. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05002517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002517.